Vertex Pharmaceuticals was founded in 1989 and is headquartered in Boston, US

Vertex Pharmaceuticals has an office in Boston

Boston, US (HQ)

50 Northern Ave

Vertex Pharmaceuticals's revenue was reported to be $714.7 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 714.7 m |

## Net income (Q1, 2017) | 249.5 m |

## EBIT (Q1, 2017) | 270.8 m |

## Market capitalization (17-Aug-2017) | 37.4 b |

## Cash (31-Mar-2017) | 1 b |

Vertex Pharmaceuticals's current market capitalization is $37.4 b.

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 1.2 b | 580.4 m | 1 b | 1.7 b |

## Revenue growth, % | (52%) | 78% | 65% | |

## R&D expense | 1 b | |||

## Operating expense total | 2.1 b | 1.3 b | 1.5 b | 1.7 b |

## EBIT | (903.4 m) | (692.4 m) | (466.9 m) | 9.9 m |

## EBIT margin, % | (75%) | (119%) | (45%) | 1% |

## Interest expense | 22.7 m | 72.9 m | 84.2 m | 81.4 m |

## Interest income | 22.7 m | |||

## Pre tax profit | (976.1 m) | |||

## Income tax expense | (288.6 m) | 7 m | 30.4 m | 16.7 m |

## Net Income | (687.6 m) | (742.7 m) | (588.2 m) | (84 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 138.4 m | 179 m | 138.5 m | 166.1 m | 309.8 m | 398.1 m | 431.6 m | 413.8 m | 714.7 m |

## R&D expense | 224.8 m | 190.9 m | 215.6 m | 223.9 m | 246.3 m | 255.9 m | 271 m | 272.4 m | 273.6 m |

## Operating expense total | 224.8 m | 190.9 m | 215.6 m | 223.9 m | 246.3 m | 255.9 m | 271 m | 272.4 m | 273.6 m |

## EBIT | (180.8 m) | (142.2 m) | (172 m) | (171.2 m) | (70 m) | (14.3 m) | 3.4 m | (18.7 m) | 270.8 m |

## EBIT margin, % | (131%) | (79%) | (124%) | (103%) | (23%) | (4%) | 1% | (5%) | 38% |

## Interest expense | (15.6 m) | (20.4 m) | (21.3 m) | (21.1 m) | (21.1 m) | (20.7 m) | (20.2 m) | (20.1 m) | (16.8 m) |

## Pre tax profit | (18 m) | (39 m) | |||||||

## Income tax expense | 693 k | 3.4 m | 299 k | 30.1 m | 1.3 m | 5.5 m | 18.1 m | 503 k | 4 m |

## Net Income | (159.4 m) | (198.7 m) | (221 m) | (93.8 m) | (36.1 m) | (36.2 m) | (39.5 m) | 249.5 m |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 569.3 m | 625.3 m | 714.8 m | 1.2 b |

## Accounts Receivable | 85.5 m | 76 m | 177.6 m | 201.1 m |

## Inventories | 14.1 m | 30.8 m | 57.2 m | 77.6 m |

## Current Assets | 1.6 b | 1.5 b | 1.4 b | 1.8 b |

## PP&E | 696.9 m | 715.8 m | 697.7 m | 698.4 m |

## Goodwill | 31 m | 39.9 m | 50.4 m | 50.4 m |

## Total Assets | 2.3 b | 2.3 b | 2.5 b | 2.9 b |

## Accounts Payable | 49.3 m | 71.2 m | 74.9 m | 61.5 m |

## Current Liabilities | 397.8 m | 368.3 m | 506.3 m | 792.5 m |

## Total Liabilities | 1.6 b | |||

## Additional Paid-in Capital | 5.3 b | 5.8 b | 6.2 b | 6.5 b |

## Retained Earnings | (4 b) | (4.7 b) | (5.3 b) | (5.4 b) |

## Total Equity | 1.1 b | 1.3 b | ||

## Financial Leverage | 2.3 x | 2.2 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 420.6 m | 718.6 m | 664.9 m | 870.5 m | 756.3 m | 604.2 m | 605.9 m | 719.7 m | 1 b |

## Accounts Receivable | 81.8 m | 114.3 m | 80.3 m | 94.5 m | 165.3 m | 181.9 m | 189.4 m | 182.2 m | 208 m |

## Inventories | 12 m | 16.8 m | 34.1 m | 42.1 m | 49.2 m | 63.2 m | 66.6 m | 71.8 m | 82 m |

## Current Assets | 1.3 b | 1.7 b | 1.4 b | 1.3 b | 1.4 b | 1.4 b | 1.5 b | 1.5 b | 1.9 b |

## PP&E | 730 m | 720.9 m | 708.6 m | 713.4 m | 706.7 m | 690.5 m | 690.6 m | 687.6 m | 708.4 m |

## Goodwill | 31 m | 31 m | 39.9 m | 50.4 m | 50.4 m | 50.4 m | 50.4 m | 50.4 m | 50.4 m |

## Total Assets | 2.1 b | 2.4 b | 2.2 b | 2.4 b | 2.4 b | 2.5 b | 2.5 b | 2.6 b | 2.9 b |

## Accounts Payable | 55.4 m | 38.5 m | 43.5 m | 72.7 m | 78.9 m | 75.2 m | 51.3 m | 50.9 m | 63.1 m |

## Current Liabilities | 363 m | 372.2 m | 302.4 m | 373.8 m | 375 m | 552 m | 622.9 m | 722.8 m | 489.8 m |

## Additional Paid-in Capital | 5.5 b | 5.7 b | 5.9 b | 6 b | 6.1 b | 6.3 b | 6.4 b | 6.4 b | 6.6 b |

## Retained Earnings | (4.4 b) | (4.5 b) | (4.9 b) | (5.1 b) | (5.2 b) | (5.3 b) | (5.4 b) | (5.4 b) | (5.1 b) |

## Total Equity | 1 b | 1.1 b | 1.1 b | 1.2 b | 1.2 b | 1.7 b | |||

## Financial Leverage | 2.3 x | 2.3 x | 2.2 x | 2.2 x | 2.2 x | 1.8 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (687.6 m) | (742.7 m) | (588.2 m) | (84 m) |

## Depreciation and Amortization | 48.4 m | 63.3 m | 62.3 m | 61.4 m |

## Accounts Receivable | 53.4 m | 7.4 m | (100 m) | (33 m) |

## Inventories | 7.1 m | (16 m) | (23 m) | (16.5 m) |

## Accounts Payable | (49.2 m) | 25 m | (1.7 m) | (11.7 m) |

## Cash From Operating Activities | (51.6 m) | (513.2 m) | (365.4 m) | |

## Cash From Investing Activities | (54.1 m) | 74 m | 268.9 m | 104.5 m |

## Cash From Financing Activities | 180.9 m | 497.4 m | 188.9 m | 133.3 m |

## Interest Paid | 11 m | 8.7 m | 85.6 m | 83.7 m |

## Income Taxes Paid | 2.8 m | 1.2 m | 1.8 m |

USD | Q2, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|

## Net Income | (159.4 m) | (198.7 m) | (221 m) | (93.8 m) | (36.1 m) | (36.2 m) | (39.5 m) | 249.5 m |

## Accounts Receivable | 94.5 m | 165.3 m | 181.9 m | 189.4 m | 182.2 m | 208 m | ||

## Inventories | 42.1 m | 49.2 m | 63.2 m | 66.6 m | 71.8 m | 82 m | ||

## Accounts Payable | 72.7 m | 78.9 m | 75.2 m | 51.3 m | 50.9 m | 63.1 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 332.4 k |

## Financial Leverage | 1.8 x |